TED-A9
Phase 2A therapy of midbrain dopaminergic progenitors differentiated from human embryonic stem cells; 24-month follow-up of 12 patients in a Korean Phase 1/2a trial is complete.
FROM PUBLIC EVENTS · 2026-11-18
Early clinical · first deals Has released 24-month Korean Phase 1/2a results for its Parkinson's cell therapy TED-A9 and is preparing a US late-stage trial. Also seen: Global approvals · expansion
Roles often seen at this stageClinical & PV · Regulatory affairs · Manufacturing & MSAT
A company developing stem-cell-based treatments for neurological and intractable diseases, led by TED-A9, an embryonic-stem-cell-derived cell therapy for Parkinson's disease.
A therapy of midbrain dopaminergic progenitors differentiated from human embryonic stem cells; 24-month follow-up of 12 patients in a Korean Phase 1/2a trial is complete.
Completed a Pre-IND meeting with the US FDA in October 2025; Catalent handles technology transfer for US manufacturing.
Released 24-month follow-up results from the TED-A9 Phase 1/2a trial.
Attended BIO USA 2026 to hold partnering meetings on TED-A9.
Raised about KRW 40 billion to prepare for Phase 3.
Official role guide
Observed 2026-11-18
Information from a role guide does not establish a current vacancy.
A brief based on selected official material, not an exhaustive product or vacancy list.